• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发并验证一种在行政索赔数据库中识别甲型血友病患者的算法。

Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database.

机构信息

HealthCore, Wilmington, DE, USA.

HealthCore, Wilmington, DE, USA.

出版信息

Value Health. 2018 Sep;21(9):1098-1103. doi: 10.1016/j.jval.2018.03.008. Epub 2018 May 7.

DOI:10.1016/j.jval.2018.03.008
PMID:30224115
Abstract

BACKGROUND

The accuracy with which hemophilia A can be identified in claims databases is unknown.

OBJECTIVE

Develop and validate an algorithm using predictive modeling supported by machine learning to identify patients with hemophilia A in an administrative claims database.

METHODS

We first created a screening algorithm using medical and pharmacy claims to identify potential hemophilia A patients in the US HealthCore Integrated Research Database between January 1, 2006 and April 30, 2015. Medical records for a random sample of patients were reviewed to confirm case status. In this validation sample, we used lasso logistic regression with cross-validation to select covariates in claims data and develop a predictive model to estimate the probability of being a confirmed hemophilia A case.

RESULTS

The screening algorithm identified 2,252 patients and we reviewed medical records for 400 of these patients. The screening algorithm had a positive predictive value (PPV) of 65%. The predictive model identified 18 predictors of being a hemophilia A case or noncase. The strongest predictors of case status included male sex, factor VIII therapy, office visits for hemophilia A, and hospitalizations for hemophilia A. The strongest predictors of noncase status included hospitalizations for reasons other than hemophilia A and factor VIIa therapy. A probability threshold of ≥0.6 resulted in a PPV of 94.7% (95% CI: 92.0-97.5) and sensitivity of 94.4% (95% CI: 91.5-97.2).

CONCLUSIONS

We developed and validated an algorithm to identify hemophilia A cases in an administrative claims database with high sensitivity and high PPV.

摘要

背景

在理赔数据库中识别血友病 A 的准确性尚不清楚。

目的

开发并验证一种使用机器学习支持的预测建模算法,以在行政理赔数据库中识别血友病 A 患者。

方法

我们首先使用医疗和药房理赔数据创建了一个筛选算法,以在 2006 年 1 月 1 日至 2015 年 4 月 30 日期间在美国 HealthCore 综合研究数据库中识别潜在的血友病 A 患者。对随机抽样患者的医疗记录进行了回顾,以确认病例状态。在验证样本中,我们使用带有交叉验证的套索逻辑回归选择理赔数据中的协变量,并开发了一个预测模型来估计成为确诊血友病 A 病例的概率。

结果

筛选算法确定了 2252 名患者,我们对其中 400 名患者的医疗记录进行了回顾。筛选算法的阳性预测值(PPV)为 65%。预测模型确定了 18 个预测血友病 A 病例或非病例的因素。病例状态的最强预测因素包括男性、VIII 因子治疗、血友病 A 的门诊就诊和血友病 A 的住院治疗。非病例状态的最强预测因素包括非血友病 A 原因的住院治疗和因子 VIIa 治疗。概率阈值≥0.6 导致 PPV 为 94.7%(95%CI:92.0-97.5)和敏感性为 94.4%(95%CI:91.5-97.2)。

结论

我们开发并验证了一种在理赔数据库中识别血友病 A 病例的算法,具有高敏感性和高 PPV。

相似文献

1
Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database.开发并验证一种在行政索赔数据库中识别甲型血友病患者的算法。
Value Health. 2018 Sep;21(9):1098-1103. doi: 10.1016/j.jval.2018.03.008. Epub 2018 May 7.
2
Predictive model algorithms identifying early and advanced stage ER+/HER2- breast cancer in claims data.预测模型算法在理赔数据中识别早期和晚期 ER+/HER2- 乳腺癌。
Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):171-178. doi: 10.1002/pds.4681. Epub 2018 Nov 9.
3
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.开发和验证一种预测模型算法,以在美国行政索赔数据中识别 2 型糖尿病成人中的过敏反应。
Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):918-926. doi: 10.1002/pds.5257. Epub 2021 May 5.
4
Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.在美国一个大型行政索赔数据库中,开发并验证一种用于识别癫痫患者队列中尿潴留情况的算法。
Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):413-21. doi: 10.1002/pds.3975. Epub 2016 Feb 17.
5
Development and validation of a case definition to identify hemophilia in administrative data.开发和验证一种病例定义,以在行政数据中识别血友病。
Thromb Res. 2021 Aug;204:16-21. doi: 10.1016/j.thromres.2021.05.013. Epub 2021 May 28.
6
Chart validation of an algorithm for identifying hereditary progressive muscular dystrophy in healthcare claims.基于医保理赔数据识别遗传性进行性肌营养不良症的算法的验证。
BMC Med Res Methodol. 2019 Aug 9;19(1):174. doi: 10.1186/s12874-019-0816-7.
7
Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database.美国行政数据库中识别他汀类药物不耐受算法的开发与验证
Value Health. 2016 Sep-Oct;19(6):852-860. doi: 10.1016/j.jval.2016.03.1858. Epub 2016 May 11.
8
Validation of an Algorithm for Claims-based Incidence of Prostate Cancer.基于索赔的前列腺癌发病率算法验证。
Epidemiology. 2019 May;30(3):466-471. doi: 10.1097/EDE.0000000000001007.
9
Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation.美国自动索赔中的特发性肺纤维化。发病率、患病率和算法验证。
Am J Respir Crit Care Med. 2015 Nov 15;192(10):1200-7. doi: 10.1164/rccm.201504-0818OC.
10
Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel.验证食品和药物管理局 Mini-Sentinel 中的过敏反应。
Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1205-13. doi: 10.1002/pds.3505. Epub 2013 Sep 5.

引用本文的文献

1
Artificial Intelligence in the Management of Hereditary and Acquired Hemophilia: From Genomics to Treatment Optimization.人工智能在遗传性和获得性血友病管理中的应用:从基因组学到治疗优化
Int J Mol Sci. 2025 Jun 25;26(13):6100. doi: 10.3390/ijms26136100.
2
Artificial Intelligence in Hemophilia Management: Revolutionizing Patient Care and Future Directions.血友病管理中的人工智能:变革患者护理及未来方向
Acta Haematol. 2025 Jun 24:1-10. doi: 10.1159/000546954.
3
Burden of Haemophilia A in South Korea: A Serial Cross-Sectional Study From 2008 to 2021.
韩国甲型血友病负担:2008年至2021年的系列横断面研究
Haemophilia. 2025 Jul;31(4):687-695. doi: 10.1111/hae.70064. Epub 2025 May 30.
4
Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review.遗传性凝血障碍中的数字技术:一项系统综述
Hamostaseologie. 2024 Dec;44(6):446-458. doi: 10.1055/a-2415-8646. Epub 2024 Dec 10.
5
Health care costs and resource use of managing hemophilia A: A targeted literature review.管理甲型血友病的医疗成本和资源利用:有针对性的文献综述。
J Manag Care Spec Pharm. 2023 Jun;29(6):647-658. doi: 10.18553/jmcp.2023.29.6.647.
6
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.在美国,接受 FVIII 预防治疗的商业保险成年血友病 A 患者的医疗保健费用和资源利用情况。
J Manag Care Spec Pharm. 2022 Apr;28(4):449-460. doi: 10.18553/jmcp.2021.21368. Epub 2021 Dec 27.
7
Identification and Validation of Hemophilia-Related Outcomes on Japanese Electronic Medical Record Database (Hemophilia-REAL V Study).日本电子病历数据库中血友病相关结局的识别与验证(血友病-REAL V研究)
J Blood Med. 2021 Jul 6;12:571-580. doi: 10.2147/JBM.S313371. eCollection 2021.
8
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.血友病 A 成年患者接受因子 VIII 预防治疗的卫生保健资源利用和成本:一项行政索赔分析。
J Manag Care Spec Pharm. 2021 Mar;27(3):316-326. doi: 10.18553/jmcp.2021.27.3.316.